John Pribis
Fondatore presso Solu Therapeutics
Posizioni attive di John Pribis
Società | Posizione | Inizio | Fine |
---|---|---|---|
Solu Therapeutics
Solu Therapeutics Pharmaceuticals: MajorHealth Technology Solu Therapeutics is an American precision-medicine company focused on developing therapeutics to eliminate disease-driving cells in cancer, immunology, and autoimmunity. The company is located in the US. The company's proprietary cytotoxicity targeting chimera (cytac) platform and drug candidates, licensed from GSK, unlock antibody-intractable cell surface targets, providing the capability to develop next-generation medicines that harness the power of biologics with the vast target binding space of small molecules. | Fondatore | - | - |
Corporate Officer/Principal | - | - |
Storia della carriera di John Pribis
Precedenti posizioni note di John Pribis
Società | Posizione | Inizio | Fine |
---|---|---|---|
Flagship Pioneering
Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Analista di Private Equity | 01/12/2019 | - |
Formazione di John Pribis
Baylor College of Medicine | Graduate Degree |
Drexel University | Undergraduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 5 |
Posizioni
Private Equity Analyst | 1 |
Graduate Degree | 1 |
Undergraduate Degree | 1 |
Settori
Consumer Services | 3 |
Finance | 2 |
Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 2 |
---|---|
Flagship Pioneering
Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Solu Therapeutics
Solu Therapeutics Pharmaceuticals: MajorHealth Technology Solu Therapeutics is an American precision-medicine company focused on developing therapeutics to eliminate disease-driving cells in cancer, immunology, and autoimmunity. The company is located in the US. The company's proprietary cytotoxicity targeting chimera (cytac) platform and drug candidates, licensed from GSK, unlock antibody-intractable cell surface targets, providing the capability to develop next-generation medicines that harness the power of biologics with the vast target binding space of small molecules. | Health Technology |
- Borsa valori
- Insiders
- John Pribis
- Esperienza